At a glance
- Originator Foamix
- Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Eye disorder therapies; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration; Blepharitis; Chlamydial infections; Diabetic macular oedema; Glaucoma; Ophthalmic infections; Rosacea
Most Recent Events
- 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
- 17 Jul 2018 No development reported - Clinical-Phase-Unknown for Age-related macular degeneration (Topical gel)
- 17 Jul 2018 No development reported - Clinical-Phase-Unknown for Blepharitis (Topical gel)